
### [MONDO:0007950](http://purl.obolibrary.org/obo/MONDO_0007950)
**Label:** mastocytosis

**Subclasses:** [MONDO:0019315](http://purl.obolibrary.org/obo/MONDO_0019315) (diffuse cutaneous mastocytosis), [MONDO:0019316](http://purl.obolibrary.org/obo/MONDO_0019316) (Maculopapular cutaneous mastocytosis), [MONDO:0016586](http://purl.obolibrary.org/obo/MONDO_0016586) (systemic mastocytosis), [MONDO:0019023](http://purl.obolibrary.org/obo/MONDO_0019023) (cutaneous mastocytosis), [MONDO:0020331](http://purl.obolibrary.org/obo/MONDO_0020331) (indolent systemic mastocytosis), [MONDO:0020333](http://purl.obolibrary.org/obo/MONDO_0020333) (aggressive systemic mastocytosis), [MONDO:0020334](http://purl.obolibrary.org/obo/MONDO_0020334) (mast cell leukemia), 

**Corr. equiv. classes:** [Orphanet:2467](http://www.orpha.net/ORDO/Orphanet_2467), [Orphanet:79457](http://www.orpha.net/ORDO/Orphanet_79457), [OMIM:154800](http://purl.obolibrary.org/obo/OMIM_154800), [Orphanet:66646](http://www.orpha.net/ORDO/Orphanet_66646), [Orphanet:98848](http://www.orpha.net/ORDO/Orphanet_98848), [Orphanet:98850](http://www.orpha.net/ORDO/Orphanet_98850), [Orphanet:98851](http://www.orpha.net/ORDO/Orphanet_98851), [Orphanet:79456](http://www.orpha.net/ORDO/Orphanet_79456), 

**Class expressions from DL-Learner:**

- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0100852](http://purl.obolibrary.org/obo/HP_0100852) (Abnormal fear/anxiety-related behavior) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0100495](http://purl.obolibrary.org/obo/HP_0100495) (Mastocytosis) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0100494](http://purl.obolibrary.org/obo/HP_0100494) (Abnormal mast cell morphology) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0031466](http://purl.obolibrary.org/obo/HP_0031466) (Impairment in personality functioning) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0030956](http://purl.obolibrary.org/obo/HP_0030956) (Abnormality of cardiovascular system electrophysiology) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0012638](http://purl.obolibrary.org/obo/HP_0012638) (Abnormality of nervous system physiology) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0012531](http://purl.obolibrary.org/obo/HP_0012531) (Pain) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0011849](http://purl.obolibrary.org/obo/HP_0011849) (Abnormal bone ossification) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0011843](http://purl.obolibrary.org/obo/HP_0011843) (Abnormality of skeletal physiology) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0011842](http://purl.obolibrary.org/obo/HP_0011842) (Abnormality of skeletal morphology) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0011675](http://purl.obolibrary.org/obo/HP_0011675) (Arrhythmia) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0011122](http://purl.obolibrary.org/obo/HP_0011122) (Abnormality of skin physiology) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0011024](http://purl.obolibrary.org/obo/HP_0011024) (Abnormality of the gastrointestinal tract) 62.50%
- [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) and [HP:0011001](http://purl.obolibrary.org/obo/HP_0011001) (Increased bone mineral density) 62.50%
- [HP:0004349](http://purl.obolibrary.org/obo/HP_0004349) (Reduced bone mineral density) and [HP:0005547](http://purl.obolibrary.org/obo/HP_0005547) (Myeloproliferative disorder) 62.50%


